ALX Oncology’s (ALXO) Overweight Rating Reiterated at Cantor Fitzgerald

ALX Oncology (NASDAQ:ALXO)‘s stock had its “overweight” rating reissued by research analysts at Cantor Fitzgerald in a report released on Wednesday,Benzinga reports.

Separately, HC Wainwright reissued a “buy” rating and set a $25.00 target price on shares of ALX Oncology in a research note on Wednesday. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, ALX Oncology has an average rating of “Moderate Buy” and an average target price of $8.50.

ALX Oncology Trading Down 19.6 %

Shares of ALXO stock opened at $1.48 on Wednesday. ALX Oncology has a 1 year low of $1.19 and a 1 year high of $17.83. The firm has a market capitalization of $78.06 million, a PE ratio of -0.50 and a beta of 1.04. The stock has a fifty day moving average of $1.49 and a two-hundred day moving average of $3.37. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.82 and a current ratio of 4.82.

Insider Buying and Selling

In related news, Director Rekha Hemrajani purchased 30,000 shares of the company’s stock in a transaction on Monday, December 2nd. The shares were bought at an average price of $1.55 per share, with a total value of $46,500.00. Following the completion of the acquisition, the director now owns 33,000 shares of the company’s stock, valued at approximately $51,150. This represents a 1,000.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 33.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On ALX Oncology

Hedge funds have recently modified their holdings of the stock. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of ALX Oncology by 394.8% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,517 shares of the company’s stock valued at $39,000 after purchasing an additional 5,200 shares during the period. Hsbc Holdings PLC purchased a new stake in ALX Oncology during the second quarter valued at about $63,000. AQR Capital Management LLC boosted its holdings in shares of ALX Oncology by 50.7% in the second quarter. AQR Capital Management LLC now owns 18,079 shares of the company’s stock worth $109,000 after buying an additional 6,080 shares during the period. SG Americas Securities LLC increased its position in shares of ALX Oncology by 33.6% in the third quarter. SG Americas Securities LLC now owns 27,394 shares of the company’s stock worth $50,000 after acquiring an additional 6,888 shares in the last quarter. Finally, Algert Global LLC acquired a new stake in shares of ALX Oncology during the second quarter valued at approximately $249,000. 97.97% of the stock is currently owned by institutional investors and hedge funds.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.